India approves Novo Nordisk’s weight loss drug Wegovy for fatty liver disease
The Central Drugs Standard Control Organization has approved Novo Nordisk's drug Wegovy for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH). This marks the first time a GLP-1 receptor agonist has been approved in India for this specific liver condition.
Why it matters
This approval expands treatment options for patients suffering from fatty liver disease, a condition often linked to obesity and metabolic health.
The Central Drugs Standard Control Organization (CDSCO) has approved Danish major Novo Nordisk’s weight loss drug Wegovy (semaglutide injection 2.4 mg) for a new indication — fatty liver disease.
It has become the first and only GLP-1 RA to be approved both globally and in India for the treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis along with a reduced calorie diet and increased physical activity. MASH is a liver disease that develops due to excess fat buildup in the liver, causing chronic inflammation and liver damage, Novo Nordisk India said on Friday.
“This approval is an important milestone, giving doctors and patients a new option for people at risk of MASH while also helping to address obesity and related heart and metabolic diseases,” Novo Nordisk India managing director Vikrant Shrotriya said.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in